GeneDx Holdings Corp. (WGS) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. ...

Analyst’s Disclosure: I/we have a beneficial long position in the shares of WGS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Although there are no personal account positions, SOME STOCKS MENTIONED CAN ALREADY BE PART OF THE PORTFOLIOS OF FAMILY AND ASSOCIATES and reti ...

GeneDx Holdings Corp. (WGS) is slated to report its first-quarter 2025 results on April 30, before the market opens.The renowned genetic testing company reported adjusted earnings of 70 cents per share in the last reported quarter, topping the Zacks Consensus Estimate by a staggering 250%. GeneDx surpassed estimates in each of the trailing four quarters, the average surprise being 120.05%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)WGS’ Q1 EstimatesThe Zacks Consensus Estimate ...

Michael Wiggins De Oliveira is an inflection investor. This means buying into cheap companies at the moment when their narrative is changing and the business is on a path toward becoming significantly more profitable over the next year.With a focus on tech and “the Great Energy Transition (including uranium)”, Michael runs a concentrated portfolio with approximately 15 to 20 stocks and an average holding period of 18 months. Through his 10+ years analyzing countless companies, Michael has accumulated outsta ...

NEW YORK, March 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  GeneDx Holdings Corp ("GeneDx" or the "Company") (NASDAQ: WGS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether GeneDx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On February 5, 2025, Gri ...

Investors might want to bet on GeneDx Holdings Corp. (WGS) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number 001-39482 GeneDx Holdings Corp. (Exact name of registrant as specified in its charter) Delaware 85-1966 ...

GeneDx Holdings (NASDAQ: WGS ) is essentially a genomics company that does genome and exome testing. So far, they have built an extensive genetic database that links at least 400 illnesses to specific genes. This matters because this genetic dataset can helpMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, a graduate degree ...

GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.20 per share. This compares to loss of $0.59 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 250%. A quarter ago, it was expected that this company would post a loss of $0.19 per share when it actually produced earnings of $0.04, delivering a surprise of 121.05%.Over the last four quarters, the company ha ...

GeneDx J.P. Morgan Healthcare Conference January 2025 San Francisco, California Forward Looking Statements This presentation contains forward-looking statements under the meaning of the Private Secunities Litigation Reform Act of 1995. Forward-looking state relate to historical facts and events and such statements and opinions pertaining to the future that, for example, contain wording such as "may," "might. "expect," "intend," "plan, " fobjective," "believe, " "estimate, " "predict, " "poeitial," "onninus, ...